Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: Safety, pharmacokinetics, and antiretroviral activity

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3877-3882

  Riddler, Sharon A ^a,f   Havlir, Diane ^b   Squires, Kathleen E ^d   Kerr, Brad ^c   Lewis, Ronald H ^c   Yeh, Kuang ^e   Wynne, Linda Hawe ^e   Zhong, Ling ^e   Peng, Yahong ^e   Deutsch, Paul ^e   Saah, Alfred ^e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; VIRUS INHIBITION; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

ADULT; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; NELFINAVIR;

EID: 0036896462     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3877-3882.2002     Document Type: Article

References (10)

1. Cameron, D. W., A. J. Japour, A. Y. Xu, Hsu, J. Mellors, C. Farthing, C. Cohen, D. Poretz, M. Markowitz, S. Follansbee, J. B. Angel, D. McMahon, D. Ho, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
2. Chesney, M. A. 2000. Factors affecting adherence to antiretroviral therapy. Clin. Infect. Dis. 30(Suppl. 2):S171-S176.
3. Condra, J. H., C. J. Petropoulos, R. Ziermann, W. A. Schleif, M. Shivaprakash, and E. A. Emini. 2000. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:758-765.
4. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Melbohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
5. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
6. Jackson, K. A., S. E. Rosenbaum, B. M. Kerr, Y. K. Pithavala, G. Yuen, and M. N. Dudley. 2000. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob. Agents Chemother. 44:1832-1837.
7. Powderly, W. G., and P. Tebas. 1999. Nelfinavir, a new protease inhibitor: Early clinical results. AIDS 13(Suppl. 1):S41-S48.
8. Wu, E. Y., J. M. Wilkinson, D. G. Naret, V. L. Daniels, L. J. Williams, D. A. Khalil, and B. V. Shetty. 1997. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 695:373-380.
9. Yeh, K. C., and R. D. Small. 1989. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J. Pharmacokinet. Biopharm. 17:721-727.
10. Zhong, L., and K. C. Yeh. 1999. Determination of indinavir in human cerebrospinal fluid and plasma by solid-phase extraction and high-performance liquid chromatography with column switching. J. Chromatogr. B 734:63-71.